Crinetics Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
De CEO Crinetics Pharmaceuticals is R. Struthers, benoemd in Dec2008, heeft een ambtstermijn van 17.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.63M, bestaande uit 6.2% salaris en 93.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.14% van de aandelen van het bedrijf, ter waarde $ 101.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 5.8 jaar.
Belangrijke informatie
R. Struthers
Algemeen directeur
US$11.6m
Totale compensatie
| Percentage CEO-salaris | 6.18% |
| Dienstverband CEO | 17.6yrs |
| Eigendom CEO | 1.1% |
| Management gemiddelde ambtstermijn | 5.1yrs |
| Gemiddelde ambtstermijn bestuur | 5.8yrs |
Recente managementupdates
Recent updates
CRNX: Takeover Offer And Delayed Rival Entry Will Shape Endocrine Outlook
Crinetics Pharmaceuticals' analyst fair value estimate has been trimmed from $97 to $90 as analysts recalibrate expectations around the $85 per share cash acquisition by Vertex Pharmaceuticals and the cluster of rating downgrades to Hold or Neutral that now anchor views closer to the agreed deal price. Analyst Commentary Analysts covering Crinetics Pharmaceuticals are now largely treating the stock as a merger arbitrage situation, with ratings concentrated around Hold or Neutral and price targets aligning closely with the agreed US$85 per share cash offer from Vertex Pharmaceuticals.Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know
Summary Vertex Pharmaceuticals Incorporated acquires Crinetics Pharmaceuticals, Inc. for $85/share, valuing the deal at ~$10bn to diversify beyond its cystic fibrosis franchise. CRNX brings PALSONIFY, a newly approved oral acromegaly therapy with blockbuster potential, and atumelnant, a Phase 3 CAH candidate, strengthening VRTX's rare disease portfolio. VRTX expects Crinetics' assets to deliver up to $5bn peak annual revenues, supporting a path toward five blockbuster products and ~$20bn revenues by 2030. The CRNX acquisition is funded by cash and debt, leveraging VRTX's strong balance sheet, with anticipated deal closure in Q3 2026 and minimal near-term financial strain. Read the full article on Seeking AlphaCRNX: Delayed Rival Entry Will Support Early Acromegaly Launch Execution
The analyst fair value estimate for Crinetics Pharmaceuticals has been revised from $108.00 to $97.00, with analysts citing a reset to more moderate revenue growth, a slightly higher discount rate, and updated assumptions around future margins and P/E multiples, even as they highlight potential benefits from delayed competitive pressure in acromegaly following the Oclaiz complete response letter. Analyst Commentary Recent research coverage on Crinetics Pharmaceuticals highlights a mix of valuation resets and constructive views on the launch setup for Palsonify in acromegaly.Crinetics Pharmaceuticals (CRNX) Stock Could Be 56.5% Undervalued After ENDO 2026 Data
Crinetics Pharmaceuticals (CRNX) is back in focus after presenting extensive new data at the Endocrine Society’s 2026 meeting, covering both its approved acromegaly drug PALSONIFY and its investigational ACTH receptor antagonist atumelnant. See our latest analysis for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals’ recent ENDO 2026 updates have arrived alongside a mixed share price picture, with a 7 day share price return of 6.98% contrasting with a year to date decline of 23.24%, while...Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders will have a reason to smile today, with the analysts...Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness
Summary Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, setting a PDUFA date of 09/24/2025. Crinetics is preparing for a fall 2025 launch of paltusotine, engaging with payers and endocrinologists to ensure broad patient access and formulary placement. Despite its valuation, Crinetics' advancements in acromegaly treatment and strong Wall Street backing make it a hold and potential acquisition on pullbacks. Read the full article on Seeking AlphaCrinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Summary Paltusotine in the treatment of acromegaly is Crinetics lead therapy with NDA filing planned in H2 2024. Crinetics has no approved drug and its lead therapy will face significant competition once approved. Investors should be aware of the high-risk nature of investing in Crinetics Pharmaceuticals. Read the full article on Seeking AlphaCrinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
Summary Positive data released from 4 patients from phase 2 study that took Atumelnant for congenital adrenal hyperplasia, showing reductions in key biomarkers of A4 and 17-OHP. An NDA submission of Paltusotine for the treatment of patients with Acromegaly expected in the 2nd half of 2024. Additional results from phase 2 open-label study, using Atumelnant for patients with CAH, to be presented at ENDO Conference on June 3rd 2024 at 12:00 to 1:30 p.m. ET. Pending positive talks with FDA, possible initiation of phase 3 study using Paltusotine for the treatment of patients with Carcinoid Syndrome by end of 2024. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$496m |
| Dec 31 2025 | US$12m | US$719k | -US$465m |
| Sep 30 2025 | n/a | n/a | -US$423m |
| Jun 30 2025 | n/a | n/a | -US$370m |
| Mar 31 2025 | n/a | n/a | -US$328m |
| Dec 31 2024 | US$11m | US$654k | -US$298m |
| Sep 30 2024 | n/a | n/a | -US$278m |
| Jun 30 2024 | n/a | n/a | -US$259m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$6m | US$614k | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
Compensatie versus markt: De totale vergoeding ($USD 11.63M ) R. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.29M ).
Compensatie versus inkomsten: De vergoeding van R. is gestegen terwijl het bedrijf verliesgevend is.
CEO
R. Struthers (64 yo)
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 17.6yrs | US$11.63m | 1.14% $ 101.2m | |
| Co-Founder & Chief Scientific Officer | 18.5yrs | US$3.83m | 0.054% $ 4.8m | |
| Chief Financial Officer | 1.4yrs | US$4.45m | 0.0067% $ 596.8k | |
| Chief Information Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Head of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Legal Officer & Corporate Secretary | 5.1yrs | geen gegevens | geen gegevens | |
| Head of Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 6.2yrs | geen gegevens | geen gegevens | |
| Chief Endocrinologist | 8.1yrs | US$2.16m | geen gegevens | |
| Head of Intellectual Property | no data | geen gegevens | geen gegevens | |
| Chief Business Officer | 4.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Medical Affairs | 2.2yrs | geen gegevens | geen gegevens |
Ervaren management: Het managementteam van CRNX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 17.7yrs | US$11.63m | 1.14% $ 101.2m | |
| Independent Chairman of the Board | 10.8yrs | US$528.62k | 0.11% $ 9.7m | |
| Independent Director | 8.4yrs | US$498.59k | 0.022% $ 1.9m | |
| Independent Director | 5.8yrs | US$500.47k | 0.015% $ 1.4m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 4.5yrs | US$507.34k | 0.013% $ 1.1m | |
| Independent Director | 8.4yrs | US$493.84k | 0.015% $ 1.4m | |
| Independent Director | 7yrs | US$500.47k | 0.0061% $ 536.7k | |
| Independent Director | 4.3yrs | US$485.47k | 0.015% $ 1.4m | |
| Member of Scientific Advisory Board | 4.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.3yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 4.3yrs | geen gegevens | geen gegevens |
Ervaren bestuur: De raad van bestuur van CRNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/19 15:59 |
| Aandelenkoers aan het einde van de dag | 2026/07/17 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Crinetics Pharmaceuticals, Inc. wordt gevolgd door 22 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Brian Skorney | Baird |
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |